Clinical Trials ArenaOriginal article
Cyclo goes forth with Niemann-Pick drug’s approval bid despite Phase III miss
RegulatoryTrappsol CycloNegative
AI Analysis
Summary
Cyclo is proceeding with regulatory approval for Trappsol Cyclo despite missing its Phase III primary endpoint in Niemann-Pick disease type C. The drug could become the third approved treatment for the rare neurological disorder if it gains regulatory greenlight.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Pursuing regulatory approval despite Phase III miss
Importance:6/10
Sentiment:
-0.30
regulatoryrare diseasePhase 3 failureNPCapproval pursuit
Read the original article
Published by Clinical Trials Arena on October 1, 2026 12:49 PM